Fulcrum Therapeutics Stock Market Value
| FULC Stock | USD 10.64 0.01 0.09% |
| Symbol | Fulcrum |
Will Pharmaceuticals sector continue expanding? Could Fulcrum diversify its offerings? Factors like these will boost the valuation of Fulcrum Therapeutics. Market participants price Fulcrum higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Fulcrum Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulcrum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Fulcrum Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Fulcrum Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Fulcrum Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Fulcrum Therapeutics.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Fulcrum Therapeutics on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Fulcrum Therapeutics or generate 0.0% return on investment in Fulcrum Therapeutics over 90 days. Fulcrum Therapeutics is related to or competes with Ocugen, Compass Therapeutics, Lexicon Pharmaceuticals, Omeros, RAPT Therapeutics, Neumora Therapeutics, and Bicycle Therapeutics. Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the... More
Fulcrum Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Fulcrum Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Fulcrum Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.33 | |||
| Information Ratio | 0.0886 | |||
| Maximum Drawdown | 53.8 | |||
| Value At Risk | (7.75) | |||
| Potential Upside | 11.56 |
Fulcrum Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Fulcrum Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Fulcrum Therapeutics' standard deviation. In reality, there are many statistical measures that can use Fulcrum Therapeutics historical prices to predict the future Fulcrum Therapeutics' volatility.| Risk Adjusted Performance | 0.088 | |||
| Jensen Alpha | 0.8043 | |||
| Total Risk Alpha | 0.1675 | |||
| Sortino Ratio | 0.1534 | |||
| Treynor Ratio | (0.54) |
Fulcrum Therapeutics February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.088 | |||
| Market Risk Adjusted Performance | (0.53) | |||
| Mean Deviation | 4.34 | |||
| Semi Deviation | 4.0 | |||
| Downside Deviation | 4.33 | |||
| Coefficient Of Variation | 1020.74 | |||
| Standard Deviation | 7.49 | |||
| Variance | 56.15 | |||
| Information Ratio | 0.0886 | |||
| Jensen Alpha | 0.8043 | |||
| Total Risk Alpha | 0.1675 | |||
| Sortino Ratio | 0.1534 | |||
| Treynor Ratio | (0.54) | |||
| Maximum Drawdown | 53.8 | |||
| Value At Risk | (7.75) | |||
| Potential Upside | 11.56 | |||
| Downside Variance | 18.75 | |||
| Semi Variance | 15.99 | |||
| Expected Short fall | (5.32) | |||
| Skewness | 3.63 | |||
| Kurtosis | 20.2 |
Fulcrum Therapeutics Backtested Returns
Fulcrum Therapeutics appears to be slightly risky, given 3 months investment horizon. Fulcrum Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0511, which denotes the company had a 0.0511 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Fulcrum Therapeutics, which you can use to evaluate the volatility of the firm. Please utilize Fulcrum Therapeutics' Mean Deviation of 4.34, downside deviation of 4.33, and Coefficient Of Variation of 1020.74 to check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Fulcrum Therapeutics holds a performance score of 4. The firm shows a Beta (market volatility) of -1.34, which means a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Fulcrum Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Fulcrum Therapeutics is expected to outperform it. Please check Fulcrum Therapeutics' jensen alpha, potential upside, accumulation distribution, as well as the relationship between the treynor ratio and expected short fall , to make a quick decision on whether Fulcrum Therapeutics' price patterns will revert.
Auto-correlation | 0.17 |
Very weak predictability
Fulcrum Therapeutics has very weak predictability. Overlapping area represents the amount of predictability between Fulcrum Therapeutics time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Fulcrum Therapeutics price movement. The serial correlation of 0.17 indicates that over 17.0% of current Fulcrum Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.17 | |
| Spearman Rank Test | 0.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.18 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Fulcrum Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fulcrum Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fulcrum Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fulcrum Therapeutics Stock:Check out Fulcrum Therapeutics Correlation, Fulcrum Therapeutics Volatility and Fulcrum Therapeutics Performance module to complement your research on Fulcrum Therapeutics. For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Fulcrum Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.